ClinicalTrials.gg
CompletedNCT05511025Updated Dec 26, 2023

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

A Phase 1 interventional study of AZD6234 and Placebo in Healthy Participants, sponsored by AstraZeneca. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-26.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Overweight by AstraZeneca — 6 open to participants now, 9 under way, 5 of them phase 3. Overweight · AstraZeneca.

Enrollment
19th of 27
54 · median 177
Started
2022
with 1 other
Phase 1
9 of 27
1 open now
Registered
13th of 27
by date

Among the 27 studies in Overweight by AstraZeneca, this one is the 19th largest by enrollment, is one of 2 that started in 2022, is one of 9 in phase 1, and was the 13th registered.

Overweight

3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.

Browse Overweight studies →

Open to participants now

6 of the 27 studies in Overweight by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 534 Overweight studies recruiting now, 159 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Overweight by AstraZeneca, or all of them as a file.
02

Study summary

A study in healthy male and female participants of non-childbearing potential who are overweight or obese.

Read the detailed description

The study will comprise of:

  • A Screening Period of maximum 28 days.
  • A Treatment Period during which participants will be resident at the Clinical Unit from three days before (Day -3 ) Investigational Medicinal Product (IMP) administration (Day 1) until at least 4 days (96 hours) after IMP administration, participants will then be discharged on the morning of Day 5.
  • Weekly outpatient visits on Days 8, 15, 22, 29, and 36 for blood sample collection, Electrocardiogram (ECGs), and adverse events (AE) recording.
  • A Follow-up Visit 6 weeks (Day 43) after the last IMP dose.

Furthermore, 3 dose levels of AZD6234 for Subcutaneous (SC) administration (Cohorts 1 to 3) and one dose level for Intravenous (IV) administration (Cohort 4) are planned to be investigated in healthy participants who are overweight or obese. The IV cohort (Cohort 4) can begin in parallel or after Cohort 3. One dose level for SC administration is planned to be investigated in Japanese participants only (Cohort 5), and up to 3 additional dose levels for SC administration are planned to be investigated in healthy participants (Cohort 6 to 8). Depending on the findings, additional (optional) dose level cohorts may be added at the discretion of the Sponsor.

03

Conditions studied

  • Healthy Participants

Keywords

  • Overweight
  • Obese
  • Non-childbearing
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written prior to any study specific procedures.
  • Healthy male and female participants aged 18 to 55 years with suitable veins for cannulation or repeated venipuncture.
  • Females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit, must not be lactating and must be of non , confirmed at the Screening Visit by fulfilling one of the following criteria:

    (i) Post menopausal defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and Follicle stimulating hormone (FSH) levels in the post menopausal range.

(ii) Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.

  • Have a (BMI) of 25 to 35 kg/m2 inclusive (at the time of screening) and weigh at least 50 kg.

For the Japanese cohort(s):

  • Participant is a native of Japan; defined as having both parents and four grandparents who are Japanese. This includes second and third generation subjects of Japanese descent whose parents or grandparents are living in a country other than Japan.
  • Have a BMI of 23 to 35 kg/m2 inclusive (at the time of screening) and weigh at least 50 kg.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study, including:

    (i) Gastroparesis (or similar) requiring treatment, or (ii) Previous surgery of the upper gastrointestinal tract, or (iii) Cardiovascular disease, including but not limited to sick sinus syndrome, valvular disease, and cardiomyopathy, or (iv) Neuromuscular or neurogenic disease, or (v) Severe vitamin D deficiency \< 12 ng/dL (as assessed by screening laboratory results or history), or (vi) Type 1 or type 2 diabetes mellitus.

  • History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP.
  • Any laboratory values with the following deviations:

    (i) > (ULN) (ii) Aspartate aminotransferase > ULN (iii) \< 60 ml/min/1.73 m2 (calculated using the CKD EPI formula) (iv) White blood cell count \< LLN (v) \< LLN (vi) Total calcium or corrected calcium/ionized calcium \< LLN or > ULN

  • Abnormal vital signs, after 10 minutes supine rest, defined as any of the following:

    (i) Systolic Blood pressure (BP) \< 90 mmHg or > 140 mmHg. (ii) Diastolic BP \< 50 mmHg or > 90 mmHg. (iii) Heart rate \< 55 or > 85 beats per minute (bpm)

  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD6234.
  • Has received another new chemical entity (defined as a compound which has not been approved for marketing) within at least 30 days or 5 half-lives (whichever is longer) of the first administration of IMP in this study. The period of exclusion begins 30 days or 5 half-lives after the last visit in the previous study, whichever is the longest.
  • Participants who are vegans or have medical dietary restrictions.
  • Vulnerable participants, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC

    Drug: AZD6234 · Drug: Placebo · Combination Product: Acetaminophen

  • Experimental
    Cohort 2

    Participants will receive a single dose of AZD6234 via an SC injection and matching volume of the placebo as a solution via SC injection

    Drug: AZD6234 · Drug: Placebo · Combination Product: Acetaminophen

  • Experimental
    Cohort 3

    Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC injection

    Drug: AZD6234 · Drug: Placebo · Combination Product: Acetaminophen

  • Experimental
    Cohort 4

    Participants will receive single ascending doses of AZD6234 via IV injection and matching volumes of the placebo as a solution via IV injection

    Drug: AZD6234 · Drug: Placebo · Combination Product: Acetaminophen

  • Experimental
    Cohort 5

    One dose level for SC administration is planned to be investigated for Japanese participants only

    Drug: AZD6234 · Drug: Placebo · Combination Product: Acetaminophen

  • Experimental
    Cohort 6

    Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC injection

    Drug: AZD6234 · Drug: Placebo · Combination Product: Acetaminophen

  • Experimental
    Cohort 7

    Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC injection

    Drug: AZD6234 · Drug: Placebo · Combination Product: Acetaminophen

  • Experimental
    Cohort 8

    Participants will receive AZD6234 via SC injection and matching volumes of placebo as a solution via SC injection

    Drug: AZD6234 · Drug: Placebo · Combination Product: Acetaminophen

Interventions

  • Participants will receive a single dose of AZD6234 as a solution via SC or IV injection

  • DrugPlacebo

    Participants will receive matching volumes of the placebo as a solution via SC or IV injection

  • Combination productAcetaminophen

    Participants will receive a single dose of acetaminophen as part of a meal

06

What researchers measure

Primary outcomes

  1. Number of participants with AEs and Serious Adverse Events(SAE)

    The safety and tolerability of AZD6234 following subcutaneous and/or intravenous administration of single ascending doses in healthy participants, including Japanese participants, who are overweight or obese will be assessed.

    Time frame: From Screening until Follow up (Day 43)

Secondary outcomes

  1. Maximum observed plasma drug concentration (Cmax)

    The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.

    Time frame: From Day 1 until Follow up (Day 43)

  2. Area under the plasma concentration-time (AUClast)

    The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.

    Time frame: From Day 1 until Follow up (Day 43)

  3. Area under plasma concentration-time curve from zero to infinity (AUCinf)

    The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.

    Time frame: From Day 1 until Follow up (Day 43)

  4. Time to reach maximum observed concentration (tmax)

    The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.

    Time frame: From Day 1 until Follow up (Day 43)

  5. Terminal rate constant (λz)

    The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.

    Time frame: From Day 1 until Follow up (Day 43)

  6. Terminal elimination half-life (t½λz)

    The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.

    Time frame: From Day 1 until Follow up (Day 43)

  7. Total body clearance of drug from plasma (IV dosing only) (CL)

    The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.

    Time frame: From Day 1 until Follow up (Day 43)

  8. Apparent total body clearance of drug from plasma (SC dosing only) (CL/F)

    The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.

    Time frame: From Day 1 until Follow up (Day 43)

  9. Volume of distribution based on the terminal phase (IV dosing only) (Vz)

    The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.

    Time frame: From Day 1 until Follow up (Day 43)

  10. Apparent volume of distribution based on the terminal phase (SC dosing only) (Vz/F)

    The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.

    Time frame: From Day 1 until Follow up (Day 43)

  11. Dose-normalized AUClast (AUClast/D)

    The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.

    Time frame: From Day 1 until Follow up (Day 43)

  12. Dose-normalized AUCinf (AUCinf/D)

    The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.

    Time frame: From Day 1 until Follow up (Day 43)

  13. Dose-normalized Cmax (Cmax/D)

    The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.

    Time frame: From Day 1 until Follow up (Day 43)

  14. Time of last observed (quantifiable) concentration (tlast)

    The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.

    Time frame: From Day 1 until Follow up (Day 43)

  15. Prevalence and incidence of anti-drug antibodies (ADAs) to AZD6234

    The immunogenicity following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.

    Time frame: Day 1, Day 15, Day 29 and at Follow up (Day 43)

  16. ADA titer

    The immunogenicity following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy subjects, including Japanese subjects, who are overweight or obese will be assessed

    Time frame: Day 1, Day 15, Day 29 and at Follow up (Day 43)

07

Study locations

2 sites
  • Research Site
    Glendale, California 91206, United States
  • Research Site
    Brooklyn, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Dec 2023, 14 months.

Of 212 industry-sponsored phase 1 interventional studies under Overweight, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 14 months is above that.

Counting every sponsor, half of 231 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2022
First posted
Aug 22, 2022
StartActual
Sep 20, 2022
Primary completionActual
Dec 19, 2023
CompletionActual
Dec 19, 2023
Last update
Dec 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05511025
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 22, 2022
Start date
Sep 20, 2022
Primary completion
Dec 19, 2023
Completion
Dec 19, 2023
Last update
Dec 26, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD6234

Start the discussion